SCHEMBL15106903

SCHEMBL15106903

C=CCc1c(Cl)cccc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.50
ALDH1A1 P00352 3/20 0.40
LMNA P02545 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
AKR1B1 P15121 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
MAOB P27338 2/20 0.35
CSNK2A1 P68400 2/20 0.35
MAPK14 Q16539 1/20 0.35
ATM Q13315 1/20 0.35
TAAR1 Q96RJ0 1/20 0.34
DPP4 P27487 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31464089 0.82 CYP2A6 (0.50) CYP2A6ALDH1A1LMNANPY1RNPY2R
SCHEMBL27573453 0.81 CYP2A6 (0.39) CYP2A6ALDH1A1SMN1; SMN2ADRB2ADRB1
SCHEMBL249069 0.80 TAAR1 (0.44) CYP2A6ALDH1A1LMNASMN1; SMN2GABRA1
SCHEMBL15106928 0.80 GABRA1 (0.39) ALDH1A1LMNAL3MBTL1SMN1; SMN2GABRA1
SCHEMBL2362467 0.80 GABRA1 (0.52) ALDH1A1LMNAGABRA1GABRB2AKR1B1
SCHEMBL170430 0.79 ALDH1A1 (0.50) CYP2A6ALDH1A1L3MBTL1SMN1; SMN2GABRA1
SCHEMBL4987129 0.79 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2GABRA1GABRB2AKR1B1
SCHEMBL5889004 0.79 GABRA1 (0.38) CYP2A6ALDH1A1SMN1; SMN2GABRA1GABRB2
SCHEMBL6546847 0.79 PDCD1 (0.41) CYP2A6ALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL15106837 0.79 MAPK1 (0.50) CYP2A6ALDH1A1L3MBTL1SMN1; SMN2GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109180500-A A kind of preparation method of N, N- dimethyl -1- alkyl biphenyl methylamine 常州大学 2019-01-11 CN disclosed
US-9309188-B2 Method for allylating and vinylating aryl, heteroaryl, alkyl, and alkene halogenides using transition metal catalysis Saitigo GmbH (DE) 2016-04-12 US disclosed
US-20130184485-A1 Method for Allylating and Vinylating Aryl, Heteroaryl, Alkyl, and Alkene Halogenides Using Transition Metal Catalysis SALTIGO GMBH (DE) 2013-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184485-A1 Method for Allylating and Vinylating Aryl, Heteroaryl, Alkyl, and Alkene Halogenides Using Transition Metal Catalysis VRK2, VRK1, GRK1 CYP2A6 1033/4885ALDH1A1 2413/4885LMNA 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.